21 reports of this reaction
2.3% of all BUTENAFINE HYDROCHLORIDE reports
#7 most reported adverse reaction
RASH is the #7 most commonly reported adverse reaction for BUTENAFINE HYDROCHLORIDE, manufactured by Bayer Healthcare LLC.. There are 21 FDA adverse event reports linking BUTENAFINE HYDROCHLORIDE to RASH. This represents approximately 2.3% of all 901 adverse event reports for this drug.
Patients taking BUTENAFINE HYDROCHLORIDE who experience rash should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
RASH is a less commonly reported adverse event for BUTENAFINE HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to rash, the following adverse reactions have been reported for BUTENAFINE HYDROCHLORIDE:
The following drugs have also been linked to rash in FDA adverse event reports:
RASH has been reported as an adverse event in 21 FDA reports for BUTENAFINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
RASH accounts for approximately 2.3% of all adverse event reports for BUTENAFINE HYDROCHLORIDE, making it a notable side effect.
If you experience rash while taking BUTENAFINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.